Tildacerfont + Placebo

Phase 2Terminated

1 views this week 0 watching💤 Quiet

Interest: 17/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Polycystic Ovary Syndrome

Conditions

Polycystic Ovary Syndrome

Trial Timeline

May 15, 2022 → Aug 31, 2023

NCT ID

NCT05370521

About Tildacerfont + Placebo

Tildacerfont + Placebo is a phase 2 stage product being developed by Spruce Biosciences for Polycystic Ovary Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT05370521. Target conditions include Polycystic Ovary Syndrome.

What happened to similar drugs?

3 of 14 similar drugs in Polycystic Ovary Syndrome were approved

Approved (3) Terminated (4) Active (7)

✅tredaptive (nicotinic acid/ laropiprant) + placeboMerckApproved

✅Placebo + EverolimusNovartisApproved

✅3 mg DRSP/20 μg EEBayerApproved

🔄Metformin XR + Saxagliptin + Saxagliptin-Metformin XRAstraZenecaPhase 3

🔄Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ERAstraZenecaPhase 3

🔄Lisinopril + Telmisartan + PlaceboMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05370521	Phase 2	Terminated	May 15, 2022	Aug 31, 2023	Polycystic Ovary Syndrome

Competing Products

20 competing products in Polycystic Ovary Syndrome

See all competitors

Product	Company	Stage	Hype Score
ABBV-CLS-628 + Placebo	AbbVie	Phase 2	42
Elagolix + Placebo	AbbVie	Phase 2	35
Metformin XR + Saxagliptin + Saxagliptin-Metformin XR	AstraZeneca	Phase 3	40
Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ER	AstraZeneca	Phase 3	40
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B	AstraZeneca	Phase 1	36
AZD4901 (oral) + Placebo to match AZD4901	AstraZeneca	Phase 2	35
IVF Antagonist Protocol	Merck	Pre-clinical	22
tredaptive (nicotinic acid/ laropiprant) + placebo	Merck	Approved	43
Lisinopril + Telmisartan + Placebo	Merck	Phase 3	40
Lisinopril + Telmisartan + Placebo	Merck	Phase 3	40
Cetrorelix acetate + Cetrorelix acetate + Recombinant Human Choriogonadotropin (r-hCG) + Recombinant human follicle stimulating hormone (r-hFSH)	Merck	Phase 3	40
Gonal-f® + Long GnRH agonist + GnRH antagonist	Merck	Pre-clinical	26
Placebo + Everolimus	Novartis	Approved	43
LIK066 + Placebo	Novartis	Phase 2	35
Octreotide + Placebo	Novartis	Phase 2/3	38
Everolimus + Calcineurin inhibitors maintenance	Novartis	Phase 3	40
Everolimus + Octreotide LAR	Novartis	Phase 2	35
Atorvastatin + Placebo	Pfizer	Pre-clinical	26
Rapamune	Pfizer	Phase 1/2	32
Sirolimus	Pfizer	Phase 2/3	34